Renal Amyloidosis in Dogs: A Retrospective Study of 91 Cases with Comparison of the Disease between S har‐ P ei and Non‐ S har‐ P ei Dogs

Background Renal amyloidosis ( RA ) is a progressive and fatal renal disease. Hypothesis Clinical and pathologic manifestations of RA differ between C hinese S har‐ P ei ( CSP s) and non‐ S har‐ P ei ( NSP s) dogs. Animals 91 client‐owned dogs. Methods Retrospective review of medical records of dogs with a histological diagnosis of RA . Clinical and clinicopathologic data, hospitalization, complications, and outcome were compared between CSP s and NSP s. Results Comorbid diseases were present in 64% of all dogs. CSP s were significantly younger compared to NSP s (median, 4.8 years; range: 3.6–17 versus median: 9.0 years; range: 2.4–11.1; P  < .0001). The frequency of hypoalbuminemia, the most common biochemical abnormality, was higher in NSP s compared to CSPs (100% versus 64.7%, respectively; P  <   .001). Median serum creatinine concentration at presentation was 5.5 mg/dL, and was 3‐fold higher in CSP s compared to NSP s ( P  =   .005). Increased urine protein : creatinine ratio was present in 96% of all dogs. Nephrotic syndrome was present in 10% of NSP s but not in CSP s. Glomerular amyloid deposition, present in both CSP s (78.6%) and NSP s (95.6%) was most commonly diffuse, global, and severe. Renal medullar amyloidosis was more common in CSP s (100%) compared to NSPs (49.0%, P  =   .002), as was extrarenal amyloid deposition. The median survival time of all dogs was 5 days (range: 0–443 days). Serum creatinine concentration was significantly and negatively associated with survival ( P  =   .025). Conclusions and Clinical Relevance The clinical and pathologic manifestations of amyloidosis differ between CSP s and NSP s. The survival time observed herein was unexpectedly low, and argues for early surveillance and management of the underlying predisposing conditions.